NASDAQ:VSTM Verastem (VSTM) Stock Forecast, Price & News $11.16 -0.04 (-0.36%) (As of 05:22 PM ET) Add Compare Share Share Today's Range$10.90▼$11.2650-Day Range$4.20▼$144.7252-Week Range$3.47▼$17.52Volume107,554 shsAverage Volume158,185 shsMarket Capitalization$186.71 millionP/E RatioN/ADividend YieldN/APrice Target$43.20 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Verastem MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside287.1% Upside$43.20 Price TargetShort InterestHealthy5.87% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.02Based on 3 Articles This WeekInsider TradingSelling Shares$8,625 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.04) to ($3.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.25 out of 5 starsMedical Sector226th out of 981 stocksPharmaceutical Preparations Industry103rd out of 475 stocks 3.4 Analyst's Opinion Consensus RatingVerastem has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $43.20, Verastem has a forecasted upside of 287.1% from its current price of $11.16.Amount of Analyst CoverageVerastem has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.87% of the outstanding shares of Verastem have been sold short.Short Interest Ratio / Days to CoverVerastem has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Verastem has recently decreased by 21.49%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVerastem does not currently pay a dividend.Dividend GrowthVerastem does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VSTM. Previous Next 2.2 News and Social Media Coverage News SentimentVerastem has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Verastem this week, compared to 2 articles on an average week.Search Interest23 people have searched for VSTM on MarketBeat in the last 30 days. This is an increase of 188% compared to the previous 30 days.MarketBeat Follows7 people have added Verastem to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verastem insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,625.00 in company stock.Percentage Held by InsidersOnly 2.90% of the stock of Verastem is held by insiders.Percentage Held by Institutions60.59% of the stock of Verastem is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Verastem are expected to grow in the coming year, from ($4.04) to ($3.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verastem is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verastem is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerastem has a P/B Ratio of 4.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Verastem (NASDAQ:VSTM) StockVerastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.Read More Receive VSTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter. Email Address VSTM Stock News HeadlinesJune 3, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR) and Verastem (VSTM)June 3, 2023 | americanbankingnews.comVerastem (NASDAQ:VSTM) Shares Gap Down to $12.24June 8, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Software" to Revolutionize WarfareThis breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>June 1, 2023 | markets.businessinsider.comMizuho Securities Keeps Their Hold Rating on Verastem (VSTM)May 31, 2023 | msn.comVerastem Oncology announces 1-for-12 reverse stock split, shares fall 3%May 31, 2023 | finance.yahoo.comVerastem Oncology Announces Reverse Stock SplitMay 30, 2023 | americanbankingnews.comVerastem (NASDAQ:VSTM) Earns Hold Rating from Analysts at StockNews.comMay 29, 2023 | uk.finance.yahoo.com0LOV.L - Verastem, Inc.June 8, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!May 29, 2023 | americanbankingnews.comShort Interest in Verastem, Inc. (NASDAQ:VSTM) Declines By 21.5%May 26, 2023 | msn.comVerastem surges 131% on updated data for ovarian cancer therapyMay 26, 2023 | msn.comVerastem Doubles after Latest Cancer NewsMay 25, 2023 | businesswire.comUpdated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with ...May 25, 2023 | finance.yahoo.comUpdated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and DefactinibMay 23, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Verastem (NASDAQ:VSTM)May 20, 2023 | americanbankingnews.comAnalysts Set Verastem, Inc. (NASDAQ:VSTM) Price Target at $3.60May 19, 2023 | americanbankingnews.comFY2023 Earnings Forecast for Verastem, Inc. Issued By Cantor Fitzgerald (NASDAQ:VSTM)May 17, 2023 | americanbankingnews.comVerastem (NASDAQ:VSTM) Rating Reiterated by Cantor FitzgeraldMay 17, 2023 | americanbankingnews.comVerastem's (VSTM) "Overweight" Rating Reaffirmed at Cantor FitzgeraldMay 16, 2023 | finance.yahoo.comVerastem Oncology Appoints Karin Tollefson, PhD, to Board of DirectorsMay 15, 2023 | americanbankingnews.comVerastem, Inc. (NASDAQ:VSTM) Short Interest Up 15.7% in AprilMay 14, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Verastem (NASDAQ:VSTM)May 13, 2023 | americanbankingnews.comHC Wainwright Cuts Verastem (NASDAQ:VSTM) Price Target to $2.00May 12, 2023 | markets.businessinsider.comVerastem (VSTM) Receives a Buy from RBC CapitalMay 11, 2023 | msn.comHC Wainwright & Co. Maintains Verastem (VSTM) Buy RecommendationMay 10, 2023 | apnews.comVerastem: Q1 Earnings SnapshotMay 10, 2023 | msn.comVerastem: Q1 Earnings InsightsSee More Headlines VSTM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VSTM Company Calendar Last Earnings3/14/2023Today6/08/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:VSTM CUSIP92337C10 CIK1526119 Webwww.verastem.com Phone(781) 292-4200FaxN/AEmployees48Year FoundedN/APrice Target and Rating Average Stock Price Forecast$43.20 High Stock Price Forecast$72.00 Low Stock Price Forecast$24.00 Forecasted Upside/Downside+292.7%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($4.4418) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-73,810,000.00 Net MarginsN/A Pretax Margin-2,843.30% Return on Equity-147.20% Return on Assets-67.91% Debt Debt-to-Equity Ratio1.20 Current Ratio5.32 Quick Ratio5.32 Sales & Book Value Annual Sales$2.60 million Price / Sales70.78 Cash FlowN/A Price / Cash FlowN/A Book Value$2.71 per share Price / Book4.06Miscellaneous Outstanding Shares16,730,000Free Float16,247,000Market Cap$184.03 million OptionableOptionable Beta0.71 Key ExecutivesBrian M. StuglikChief Executive Officer & DirectorDan PatersonPresident & Chief Operating OfficerDaniel CalkinsVP, Chief Financial & Accounting OfficerJonathan PachterChief Scientific OfficerLouis J. DenisChief Medical OfficerKey CompetitorsXOMANASDAQ:XOMAMerrimack PharmaceuticalsNASDAQ:MACKSpectrum PharmaceuticalsNASDAQ:SPPIRigel PharmaceuticalsNASDAQ:RIGLFortress BiotechNASDAQ:FBIOView All CompetitorsInsiders & InstitutionsBaker BROS. Advisors LPSold 1,467,451 shares on 5/16/2023Ownership: 12.706%Geode Capital Management LLCBought 64,245 shares on 5/16/2023Ownership: 0.944%Two Sigma Advisers LPSold 445,400 shares on 5/15/2023Ownership: 0.297%Two Sigma Investments LPSold 364,214 shares on 5/15/2023Ownership: 0.093%Dimensional Fund Advisors LPSold 63,463 shares on 5/12/2023Ownership: 0.231%View All Insider TransactionsView All Institutional Transactions VSTM Stock - Frequently Asked Questions Should I buy or sell Verastem stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VSTM shares. View VSTM analyst ratings or view top-rated stocks. What is Verastem's stock price forecast for 2023? 6 brokers have issued 1 year price objectives for Verastem's shares. Their VSTM share price forecasts range from $24.00 to $72.00. On average, they expect the company's share price to reach $43.20 in the next twelve months. This suggests a possible upside of 292.7% from the stock's current price. View analysts price targets for VSTM or view top-rated stocks among Wall Street analysts. How have VSTM shares performed in 2023? Verastem's stock was trading at $4.83 at the beginning of the year. Since then, VSTM stock has increased by 127.7% and is now trading at $11.00. View the best growth stocks for 2023 here. Are investors shorting Verastem? Verastem saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 981,400 shares, a decrease of 21.5% from the April 30th total of 1,250,000 shares. Based on an average trading volume of 649,600 shares, the days-to-cover ratio is presently 1.5 days. View Verastem's Short Interest. When is Verastem's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our VSTM earnings forecast. How were Verastem's earnings last quarter? Verastem, Inc. (NASDAQ:VSTM) issued its quarterly earnings data on Tuesday, March, 14th. The biopharmaceutical company reported ($0.96) EPS for the quarter. When did Verastem's stock split? Verastem shares reverse split on the morning of Thursday, June 1st 2023. The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What is Robert Forrester's approval rating as Verastem's CEO? 11 employees have rated Verastem Chief Executive Officer Robert Forrester on Glassdoor.com. Robert Forrester has an approval rating of 100% among the company's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Verastem own? Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (gild), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Amarin (AMRN) and Viking Therapeutics (VKTX). What is Verastem's stock symbol? Verastem trades on the NASDAQ under the ticker symbol "VSTM." Who are Verastem's major shareholders? Verastem's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baker BROS. Advisors LP (12.71%), Acadian Asset Management LLC (1.24%), Geode Capital Management LLC (0.94%), Two Sigma Advisers LP (0.30%), Dimensional Fund Advisors LP (0.23%) and Two Sigma Investments LP (0.09%). Insiders that own company stock include Brian M Stuglik, Dan Paterson, Daniel Calkins, Ra Capital Management, LP, Robert E Gagnon and Timothy J Barberich. View institutional ownership trends. How do I buy shares of Verastem? Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Verastem's stock price today? One share of VSTM stock can currently be purchased for approximately $11.00. How much money does Verastem make? Verastem (NASDAQ:VSTM) has a market capitalization of $184.03 million and generates $2.60 million in revenue each year. The biopharmaceutical company earns $-73,810,000.00 in net income (profit) each year or ($4.4418) on an earnings per share basis. How can I contact Verastem? Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The official website for the company is www.verastem.com. The biopharmaceutical company can be reached via phone at (781) 292-4200 or via email at bsullivan@verastem.com. This page (NASDAQ:VSTM) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.